Deciphering the Enigma: NAP (CP201) the Active ADNP Drug Candidate Enters Cells by Dynamin-Associated Endocytosis
- 1 July 2020
- journal article
- editorial
- Published by Springer Science and Business Media LLC in Journal of Molecular Neuroscience
- Vol. 70 (7), 993-998
- https://doi.org/10.1007/s12031-020-01632-6
Abstract
No abstract availableThis publication has 61 references indexed in Scilit:
- End Binding Proteins Are Obligatory DimersPLOS ONE, 2013
- NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: Protection against impairments in axonal transportNeurobiology of Disease, 2013
- End-binding proteins sensitize microtubules to the action of microtubule-targeting agentsProceedings of the National Academy of Sciences of the United States of America, 2013
- NAP (davunetide) rescues neuronal dysfunction in a Drosophila model of tauopathyMolecular Psychiatry, 2013
- The ADNP Derived Peptide, NAP Modulates the Tubulin Pool: Implication for Neurotrophic and Neuroprotective ActivitiesPLOS ONE, 2012
- Sporadic autism exomes reveal a highly interconnected protein network of de novo mutationsNature, 2012
- An EB1-Binding Motif Acts as a Microtubule Tip Localization SignalCell, 2009
- Bimodal modulation of tau protein phosphorylation and conformation by extracellular Zn2+ in human-tau transfected cellsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2009
- NAP protects against cyanide-related microtubule destructionJournal of Neural Transmission, 2009
- Subcellular localization and secretion of activity-dependent neuroprotective protein in astrocytesNeuron Glia Biology, 2004